Author

Constance M. Pfeiffer

Observed name: Constance Pfeiffer

Institution: Immunocore (United States)

Observed institutions: Bristol-Myers Squibb (United States), Immunocore (United States)

ORCID: 0009-0006-4290-0519

Observed ORCID: 0009-0006-4290-0519

OpenAlex ID: A5083091381

Immunotargeted therapy in melanoma: patient, provider preferences, and willingness to pay at an academic cancer center

2019 · David D. Stenehjem, Trang H. Au, et al. · Melanoma Research · 30

Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 Patients

2025 · Takami Sato, Marcus O. Butler, et al. · Clinical Cancer Research · 8

Table 3 from Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 Patients

2025 · Takami Sato, Marcus O. Butler, et al.

Table 1 from Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 Patients

2025 · Takami Sato, Marcus O. Butler, et al.

Figure 3 from Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 Patients

2025 · Takami Sato, Marcus O. Butler, et al.

Table 2 from Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 Patients

2025 · Takami Sato, Marcus O. Butler, et al.

Figure 1 from Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 Patients

2025 · Takami Sato, Marcus O. Butler, et al.

Supplementary Data 1 from Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 Patients

2025 · Takami Sato, Marcus O. Butler, et al.

Figure 2 from Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 Patients

2025 · Takami Sato, Marcus O. Butler, et al.

Data from Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 Patients

2025 · Takami Sato, Marcus O. Butler, et al.

Prognostic factors and outcomes in metastatic uveal melanoma treated with PD-1 or combined PD-1 / CTLA-4 inhibition

2017 · Markus V. Heppt, Lucie Heinzerling, et al. · Journal Der Deutschen Dermatologischen Gesellschaft

Student Opinion Regarding the Importance of Student to Preceptor Ratio

2006 · Constance M. Pfeiffer, Donald K. Woodward

Works count: 12

Citation count: 38

H-index: 2

I10-index: 1